FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce

The FDA just approved J&J's Icotyde — the first oral peptide targeting the IL-23 receptor — and the company is projecting more than five billion dollars in peak annual sales.

Meanwhile, Bicycle Therapeutics is slashing thirty percent of its workforce after the FDA shut the door on its lead cancer program, and Sandoz just locked in a five-biosimilar deal with Samsung Bioepis. Big day. Let's break it down.

Welcome to The Pharma Closeout for Wednesday, March 18th, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it. ### [TOP STORY] — FDA Approves J&J's Icotyde for Plaque Psoriasis

Lead story — and it's one the dermatology market has been waiting for. The FDA approved Icotyde, brand name for icotrokinra, J&J's oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis in patients twelve and older. Once-daily pill. Originally developed through Protagonist Therapeutics, which J&J acquired. The company is projecting north of five billion in peak annual sales. Per J&J's press release, this is the first and only targeted oral peptide that precisely blocks the IL-23 receptor.

The ICONIC clinical program behind this approval is unusually comprehensive. Four Phase 3 studies, twenty-five hundred patients, and J&J ran something you rarely see — duplicate head-to-head superiority trials against an active comparator, Bristol Myers Squibb's Sotyktu. Roughly seventy percent of patients on Icotyde achieved clear or almost clear skin. Fifty-five percent hit PASI 90 at week sixteen. And that superiority held through week fifty-two.

So here's the strategic tension. J&J is launching a pill that competes directly with its own injectable franchise. Tremfya generates billions in annual revenue. The bet — and it's a big one — is that an oral option expands the total addressable market by pulling in patients from the roughly eight million Americans with plaque psoriasis who cycle on topicals and never step up to a biologic.

I'd push back on calling that a bet. The data supports it. There's a well-documented drop-off between patients who qualify for systemic therapy and patients who actually initiate it — and needle aversion is a primary driver. What Icotyde changes is the activation energy to get into the IL-23 class. That fifty-five percent PASI 90 in an oral formulation at sixteen weeks is territory that was exclusively held by injectables. If you're a dermatologist, the conversation with your patient just got dramatically simpler.

Fair point. And the sell-side is already running with the expansion thesis. Per the company's announcement, J&J says more than five billion at peak. Citi's note pegged five-point-five billion. Jefferies went further — seven-point-five billion in peak U.S. sales alone, per their recent analysis.

The Tremfya cannibalization risk is real, but J&J clearly decided they'd rather cannibalize themselves than cede the oral space to someone else. The deeper strategic question is what this does to AbbVie's Skyrizi. The convenience gap between a daily pill and a subcutaneous injection just became the single most important competitive variable in dermatology — and Skyrizi doesn't have an oral answer.

And here's a dimension that doesn't get enough attention. If you're a payer, you now have formulary leverage you literally could not construct yesterday. Oral versus injectable in the same mechanism class opens up contracting conversations that were structurally impossible when every IL-23 option required a needle. That's not just a clinical shift — it rewrites the commercial architecture of the entire category.

That payer dynamic is going to ripple well beyond psoriasis. But speaking of companies facing structural shifts — Bicycle Therapeutics had a very different kind of day.

A rough one. Bicycle is cutting roughly thirty percent of its workforce — about eighty-six positions based on a year-end headcount of two hundred eighty-eight — after the FDA determined that the ongoing study for its lead asset zelenectide was no longer acceptable as an approval pathway. This was their most advanced program. Zelenectide had been positioned as a potential challenger to Pfizer's Padcev in metastatic urothelial carcinoma. That competitive threat is now off the table.

What makes this particularly painful is the mechanism of the setback. This wasn't a clinical failure — the efficacy question was still open. The FDA closed the regulatory door on the study design itself. That's a harder narrative for management to recover from, because it raises questions about regulatory strategy, not just science. Investors can forgive a drug that doesn't work. They're less forgiving when the path to approval collapses under you.

On the biosimilar front — Sandoz announced a partnership with Samsung Bioepis covering up to five biosimilar candidates, including SB36, referencing Takeda's Entyvio. Per the Sandoz release, they pick up global commercialization rights outside China, Hong Kong, Taiwan, Macau, and South Korea.

SB36 is the one to circle. Vedolizumab is a multi-billion-dollar IBD franchise, and pairing Samsung Bioepis development capability with Sandoz's global distribution infrastructure creates a credible path to meaningful market share on a molecule that's been difficult to biosimilar.

Two more quick items. Crossbow Therapeutics unveiled a seventy-seven-million-dollar Series B for its TCR-mimetic T cell engager platform under CEO Briggs Morrison. And TerraPower — Bill Gates' nuclear energy company — committed four hundred fifty million dollars to build a radioisotope manufacturing facility in Philadelphia focused on actinium-225. The supply chain for radiopharmaceuticals is becoming its own competitive battlefield — and the companies that lock up isotope supply now will have leverage for the next decade.

On the regulatory front, two FDA moves today worth flagging, and neither got the attention they deserve given the Icotyde noise. First — the agency opened the door to granting RMAT designations for therapies currently sitting on clinical hold. Think about what that means for cell and gene therapy developers in limbo right now. A clinical hold used to effectively freeze your regulatory pathway. This guidance says the regenerative medicine lane can stay open while you resolve the safety issue.

Which changes the math on whether a company fights through a hold or abandons the program. If RMAT status is preserved, the incentive to keep investing through the hold period goes up considerably.

Second, new draft guidance aimed at reducing animal studies in drug development. The headline sounds incremental, but for a pre-revenue biotech burning two million a month, every preclinical study you can eliminate or streamline is runway you get back. The real beneficiaries here are rare disease developers running lean.

And one policy story to track — a Maryland bill would require pharma companies to disclose financial ties to disease awareness advertising. STAT's Ed Silverman reported on it today. The industry is calling it unworkable, but legislation like this rarely stays in one state. If Maryland passes it, expect it to travel — and the compliance burden compounds fast once you're managing disclosure across multiple jurisdictions.

Looking ahead. The GSK linerixibat PDUFA date hits next Tuesday, March twenty-fourth — six days out. That's a decision point for cholestatic pruritus, a space with very limited approved options. A green light would give GSK a meaningful specialty franchise; a rejection resets the competitive clock entirely.

And keep watching Lilly. Shares have dropped seven percent since HSBC downgraded the stock from hold to reduce. Their analyst Rajesh Kumar cited pricing pressures and intensifying competition in obesity, per reporting from FiercePharma. With oral GLP-1 programs advancing across multiple companies, the market is starting to price in a world where Lilly's dominance is contestable — not certain.

That HSBC note could end up being a turning point in the consensus narrative. For months, the Street treated GLP-1 growth as essentially unbounded. If other banks follow the downgrade, we're watching the beginning of a repricing cycle — and that affects every company with an obesity-adjacent pipeline.

And that is your Pharma Closeout for Wednesday, March 18th — Icotyde rewriting the playbook in psoriasis, Bicycle hitting a regulatory wall in bladder cancer, Sandoz going deep on biosimilars with Samsung Bioepis, and Lilly facing a rare downgrade that could reshape the GLP-1 narrative. If you want to stay across this space, follow us on Spotify and drop a rating — we'll be back tomorrow.

A day like today is why we do this. We'll be back tomorrow to keep it going. See you then. ### Episode Metadata **Title:** FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce; Lilly Drops 7% on HSBC Downgrade | Mar 18, 2026 **Description:** FDA approves J&J's Icotyde — the first oral IL-23R peptide for psoriasis — with $5B+ peak sales projected. Plus Bicycle Therapeutics shelves lead cancer program zelenectide, Sandoz and Samsung Bioepis partner on five biosimilars, and Eli Lilly slides 7% on a rare HSBC downgrade. **Tags:** Icotyde, icotrokinra, Johnson & Johnson, Protagonist Therapeutics, psoriasis, FDA approval, Bicycle Therapeutics, zelenectide, Padcev, Sandoz, Samsung Bioepis, biosimilar, Entyvio, Eli Lilly, HSBC, GLP-1, obesity, Crossbow Therapeutics, TerraPower, radiopharmaceutical, actinium-225, GSK, linerixibat, RMAT, pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals #